Qu, Yali
Middleton, Michael S.
Loomba, Rohit
Glaser, Kevin J.
Chen, Jun
Hooker, Jonathan C.
Wolfson, Tanya
Covarrubias, Yesenia
Valasek, Mark A.
Fowler, Kathryn J.
Zhang, Yingzhen N.
Sy, Ethan
Gamst, Anthony C.
Wang, Kang
Mamidipalli, Adrija
Schwimmer, Jeffrey B.
Song, Bin
Reeder, Scott B.
Yin, Meng
Ehman, Richard L.
Sirlin, Claude B. http://orcid.org/0000-0002-6639-9072
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (K23DK090303, R01DK083380, R01DK088925, R01DK100651, K24DK102595, R01DK106419, U01DK061718)
Mayo Clinic Center for Individualized Medicine Imaging Biomarker Discovery Program.
National Institutes of Health (EB001981, EB017197)
Article History
Received: 29 December 2020
Revised: 25 March 2021
Accepted: 2 April 2021
First Online: 26 April 2021
Declarations
:
: The scientific guarantor of this publication is Claude B. Sirlin.
: The authors of this manuscript declare relationships with the following companies:K. J. G. has intellectual property rights and a financial interest in MR elastography technology; institution has intellectual property rights and a financial interest in MR elastography technology.J. C. has intellectual property rights and a financial interest in MR elastography technology; his institution has intellectual property rights and a financial interest in MR elastography technology. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board as is being conducted in compliance with Mayo Clinic Conflict of Interest policies.S. B. R. reports that his institution, the University of Wisconsin, receives research support from GE Healthcare.M. Y. has intellectual property rights and a financial interest in MR elastography technology; her institution has intellectual property rights and a financial interest in MR elastography technology. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and is being conducted in compliance with Mayo Clinic Conflict of Interest policies.R. L. E. has intellectual property rights and a financial interest in MR elastography technology. His institution has intellectual property rights and a financial interest in MR elastography technology. He reports grants from Resoundant Inc. His research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and is being conducted in compliance with Mayo Clinic Conflict of Interest policies.C. B. S. reports grants from GE, Siemens, Philips, Bayer, Foundation of NIH, and Gilead; personal consultation fees from Blade, Boehringer, and Epigenomics; consultation under the auspices of the University to AMRA, BMS, Exact Sciences, GE Digital, IBM-Watson, and Pfizer; lab service agreements from Enanta, Gilead, ICON, Intercept, Nusirt, Shire, Synageva, Takeda; royalties from Wolters Kluwer for educational material outside the submitted work; honoraria to the institution from Medscape for educational material outside the submitted work; ownership of stock in Livivos; serving on advisory board to Quantix Bio.J. B. S. reports grant funding from Intercept, Genfit, and Seraphina.M. S. M. reports consultation to Arrowhead, Glympse, Kowa, Median, and Novo Nordisk; lab service agreements under auspices of UCSD from Alexion, AstraZeneca, Bristol-Myers Squibb, Celgene, Enanta, Galmed, Genzyme, Gilead, Guerbet, Intercept, Ionis, Janssen, Janssen, NuSirt, Organovo, Pfizer, Roche, Sanofi, Shire, Synageva, and Takeda; stockholder Pfizer; and co-founder Quantix Bio.K. J. F. reports grants from Bayer, Median, Pfizer, and GE, consulting for Epigenomics and GE.R. L. reports grant support from Allergan, Astrazeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Cirius, Eli Lilly and Company, Galectin Therapeutics, Galmed Pharmaceuticals, GE, Genfit, Gilead, Intercept, Inventiva, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Pfizer, pH Pharma, and Siemens. He serves as a consultant or advisory board member for Alnylam/Regeneron, Arrowhead Pharmaceuticals, AstraZeneca, Bristol-Myer Squibb, CohBar, Eli Lilly, Galmed, Gilead, Glympse Bio, Inipharm, Intercept, Ionis, Janssen Inc., Merck, Metacrine, Inc., NGM Biopharmaceuticals, Novartis, Novo Nordisk, Pfizer, Promethera, Sagimet, 89 bio, and Viking Therapeutics. He also reports a financial interest in Liponexus, Inc.
: Dr. Anthony Gamst and Tanya Wolfson kindly provided statistical advice for this manuscript and were included as authors.
: Written informed consent was obtained from all subjects in this study.
: Institutional Review Board approval was obtained.
: Some study subjects or cohorts have been previously reported in the following articles (1−4). The prior articles included patients with fibrosis and so differed in their population cohorts. Also, the prior articles either did not report MRE results (1, 3) or reported only a single MRE-measured parameter (shear stiffness) (2, 4). OrderedList removed
: UnorderedList removed